Is gosatuzumab a targeted drug?

Sacituzumab govitecan is a targeted drug designed to specifically act on the Trop2 protein. Trop2 is a protein found in many breast cancer cells, and gosatuzumab aims to deliver the drug to these Trop2-rich tumor cells.

Gosatuzumab is an antibody drug conjugate (ADC), which consists of humanized anti-Trop2 monoclonal antibody (mAb) RS7 and the active metabolite SN-38. This monoclonal antibody is designed to recognize and attach to Trop2, thereby delivering the drug directly to Trop2-positive cancer cells. Once gosatuzumab binds to tumor cells, SN-38 in the drug will be released and inhibit DNA replication and cell proliferation of cancer cells with its potent topoisomerase 1 (topo 1) inhibitor activity.

Targeted drugs work differently from traditional chemotherapy drugs. Traditional chemotherapy drugs often affect normal cells and cancer cells alike, causing many side effects. Gosatuzumab has a more selective effect and mainly targets Trop2-rich cancer cells, thereby reducing the impact on normal cells and improving the effectiveness and tolerability of treatment.

Research and clinical trial results of gosatuzumab show positive results in the treatment of metastatic triple-negative breast cancer and metastatic urothelial carcinoma. It not only extends patient survival, but also improves quality of life and reduces cancer-related symptoms.

However, you still need to be aware of possible side effects and risks when using gosatuzumab. Some common side effects include nausea, neutropenia, diarrhea, fatigue, anemia, etc. In addition, gosatuzumab has some serious side effects, such as neutropenia and severe diarrhea, which require patient monitoring and communication with their doctor.